COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00330239
Recruitment Status : Completed
First Posted : May 26, 2006
Last Update Posted : October 3, 2007
Information provided by:
Medical University of South Carolina

Brief Summary:

Pharmacotherapy has demonstrated efficacy in a number of controlled trials in the treatment of PTSD. The selective serotonin reuptake inhibitors have proven particularly useful in treating this disorder. Currently there are two selective serotonin reuptake inhibitors (Zoloft® and Paxil®), that have been FDA approved for treating PTSD. Coincidentally, this same class of medications has also been shown to have efficacy in some trials in decreasing alcohol consumption in heavy drinkers. The goal of the proposed study is to preliminarily investigate the efficacy of Paxil® (paroxetine), in decreasing symptoms of PTSD as well as decreasing substance use, in individuals with concurrent substance dependence and PTSD. The type of paroxetine used in this trial will be Paxil CR®, which is a sustained release formulation of paroxetine, which has fewer side effects and greater tolerability. This is a particularly important issue in substance using populations because medication compliance is generally poor.

Two specific hypotheses will be tested. 1) Individuals who receive Paxil CR® will have a greater improvement in their PTSD symptoms (based on CAPS-2 and CGI) than those who receive placebo. 2) Individuals who receive Paxil CR® will have greater improvement in their substance use outcomes (based on UDS and TLFB) than will those who receive placebo.

Condition or disease Intervention/treatment Phase
PTSD Drug: Paroxetine CR Phase 4

Detailed Description:
Participants who meet all inclusion and no exclusion criteria will be randomized with a 1:1 ratio to receive either Paxil CR or placebo for 12 weeks. Medication will be initiated at 12.5mg/day and will be increased weekly as tolerated to a maximum dose of 50mg/day. Participants will be seen weekly and will be assessed for side effects, substance use since last visit, urine drug screen, breathalyzer readings, vital signs and symptoms of PTSD (TOP-8)at each visit. The Davidson Trauma Scale will be completed every two weeks, and the CAPS-2 and MADRS will be completed monthly. Those who complete the first 12 weeks of double-blind study medication will be eligible to receive open label medication for an additional 12 weeks. Medication will be initiated at 12.5mg and increased every 3 days as tolerated to the terminal dose in the double-blind phase, then adjusted as needed. Participants will come in for assessments every two weeks of the open-label phase. Blood will be drawn for blood chemistries and hematology at screening and weeks 12 and 24. Urine pregnancy tests will be performed for women of childbearing potential at baseline and again at weeks 4, 12 and 24.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
Study Start Date : January 2003
Study Completion Date : May 2005

Primary Outcome Measures :
  1. Clinician Administered PTSD Scale (CAPS)
  2. Clinical Global Impressions Scale

Secondary Outcome Measures :
  1. Davidson Trauma Scale
  2. Time-Line Follow-Back

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged 18 to 65
  • Outpatients who meet DSM-IV criteria for PTSD, chronic subtype, based on CAPS-1
  • Must have a minimum score of 50 on the CAPS-2 at Baseline
  • Must meet DSM-IV criteria for a substance dependence disorder in the last 3 months (excluding caffeine and nicotine)
  • Must be able to read English
  • Must give written informed consent

Exclusion Criteria:

  • Individuals with a primary psychiatric disorder other than PTSD
  • Individuals with an uncontrolled neurologic condition that could confound the results of the study (e.g. seizure disorder)
  • Individuals with an uncontrolled medical condition that may adversely affect the conduct of this trial or jeopardize subject safety
  • Concomitant use of other psychotropic medications (intermittent use of diphenhydramine and zolpidem will be allowed during the study) see concommitant meds on page 5 of the protocol
  • Women of childbearing potential who are pregnant, lactating or refuse to use adequate forms of birth control
  • Individuals who have failed an adequate trial of paroxetine in the past
  • Current suicidal or homicidal risk
  • Currently receiving trauma-specific psychotherapy
  • Individuals taking any herbal psychoactive treatments (e.g. St. John's Wart)
  • Individuals engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorder
  • Individuals, who in the investigator's opinion would be unable to comply with study procedures or assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00330239

Layout table for location information
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29464
Sponsors and Collaborators
Medical University of South Carolina
Layout table for investigator information
Principal Investigator: Susan C Sonne, PharmD Medical University of South Carolina
Principal Investigator: Kathleen T Brady, MD, PhD Medical University of South Carolina

Layout table for additonal information Identifier: NCT00330239    
Other Study ID Numbers: CPMS-857
First Posted: May 26, 2006    Key Record Dates
Last Update Posted: October 3, 2007
Last Verified: October 2007
Keywords provided by Medical University of South Carolina:
Substance Abuse
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors